SOUTH SAN FRANCISCO (dpa-AFX) - Pivotal Phase III IMbrave050 study, which investigated Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence
Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq
SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG's (RHHBY) blockbuster drug Tecentriq has been approved by the European Commission for yet another lung cancer indication - this time, as an adjuvant
LOS ANGELES, June 8, 2022 /PRNewswire/ ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals